Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas Conclusions: Thymic epithelial tumors frequently express IGF-1R and/or EGFR proteins. IGF-1R gene amplification is suggested to define an unfavorable subset for thymic epithelial tumors. Key words: insulin-like-growth factor-1 receptor, gene copy number, thymic carcinoma, thymoma, tyrosine kinase receptors introduction The primary therapy for thymomas and thymic carcinomas is surgical resection. Although complete surgical resection achieves better outcomes for encapsulated thymomas, no equally successful treatment strategy has been defined for advanced (invasive) thymomas and thymic carcinomas [1, 2] . It is therefore necessary to develop a multimodality treatment strategy for such thymic tumors.
Receptor tyrosine kinases (RTKs) have been shown to have critical roles in the proliferation, migration, and survival of many types of malignant neoplastic cells [3, 4] . Several RTK inhibitors (RTKIs) are currently demonstrating dramatic efficacy against several tumors, i.e. epidermal growth factor receptor (EGFR)-TKIs for EGFR-mutated lung carcinomas [5] and imatinib, an inhibitor of the Kit, PDGFR, and BCR-ABL tyrosine kinases, for Kit-positive gastrointestinal stromal tumor [6] . Other RTKs, such as insulin-like growth factor-1 receptor (IGF-1R) and hepatocyte growth factor receptor (c-Met), are also attractive targets for treatment of malignant tumors [7] [8] [9] [10] .
Although EGFR, HER2, and IGF-1R expression has been reported in thymic epithelial tumors [11] [12] [13] [14] , gene copy number (GCN) change was analyzed only for EGFR, amplification of which was observed in 28% of thymic epithelial tumors [11] . To our knowledge, there are no reports on IGF-1R, HER2, or c-Met GCN changes in thymic epithelial tumors. Such identification of biomarkers for selecting the patients most likely to benefit clinically from RTKIs will greatly facilitate the development of these drugs for cancer therapy.
In the present study, we analyzed thymic epithelial tumors for IGF-1R, EGFR, HER2, and c-Met protein expression by immunohistochemistry (IHC) and GCN by bright-field in situ hybridization (BISH). We also analyzed the correlations between the expression and/or the GCN status of the above RTKs and the clinical features of the tumors.
materials and methods

patient population
This study included 140 patients who underwent surgical resection of thymic tumors at the National Cancer Center Hospital between 1973 and 2009 for thymic carcinoma and between 1999 and 2009 for thymoma (Table 1 ). An institutional review board approved this study. Histologic diagnosis was based on the classification schema of the latest edition of the WHO classification [15] . bright-field in situ hybridization BISH was performed as previously described [16] . In brief, the BenchMark® XT automated slide-processing system (Ventana) was used for the dualcolor BISH assay for IGF-1R and chromosome 15 centromere (CEN15), EGFR and CEN7, HER2 and CEN17, and Met and CEN7 DNA targets. TMA sections were baked and deparaffinized. Deparaffinized tissue sections were pretreated with a combination of heat treatment with reaction buffer (Tris-based pH 7.6 solution, Ventana) or CC2 (Ventana) and ISH Protease 2 or ISH Protease 3 (Ventana) for unmasking DNA targets. BISH assays were completed with the sequential probe hybridization protocol for EGFR targets or the probe co-hybridization protocol for IGF1-R, HER2, and Met targets.
BISH analysis
We evaluated the BISH signals for the IGF-1R, EGFR, HER2, and Met probes at magnifications of ×400 and ×600 using an Olympus BX50 microscope (Olympus, Tokyo, Japan). The University of Colorado Cancer Center criteria were used for IGF-1R, EGFR, and Met gene status to classify the BISH-high results into gene amplification or high polysomy [16, 18] . For the evaluation of HER2, the HER2 to CEN17 ratios were calculated according to the ASCO/CAP guidelines [17] .
statistical analysis
We analyzed thymomas and thymic carcinomas and categorized the former into three groups: type A + AB, type B1 + B2, and type B3
thymomas. The Mann-Whitney U test was used for continuous variables, and the χ 2 test or Fisher's exact test was used for categorical variables.
A P-value of ≤ 0.05 was regarded as significant. Overall survival (OS) curves were calculated using the Kaplan-Meier method. Univariate survival analysis was performed using the log-rank test and Cox proportional hazard regression. In the multivariate Cox model, variables with P < 0.10 from Wald's test of the univariate model were included. The log-rank test was used for comparison between curves. A P-value of 0.05 or less was regarded as significant. The cases whose BISH results were difficult to assess were excluded as missing data. Samples were excluded when the control signals for CEN15, CEN7, and CEN17 and/or the target gene signal were negative or only faintly positive. The numbers of cases missing data were seven and two for IGF-1R and EGFR, respectively: two of the missing data points were from the 1980s, four from the 1990s, and one from 2002.
results clinicopathologic backgrounds Table 1 shows the clinicopathologic backgrounds. We have already reported the clinicopathologic significance of hormone receptor expression in the same cohort [19] . The combined median follow-up time was 51.4 months (56.7 months for thymoma and 41.9 months for thymic carcinoma), the combined mean follow-up time was 64.6 months (62.2 months for thymoma and 71.2 months for thymic carcinoma), and the 10-year survival rate in this patient cohort was 74.0% (95% confidence interval 63.0% to 85.0%). The histological type of thymic carcinoma was squamous cell carcinoma (Sq) except for 1 adenocarcinoma, leaving 36 Sqs. Thirty-one patients (25 thymic carcinoma, 5 type B1 + B2 thymoma, and 1 type B3 thymoma) received adjuvant therapy before or after surgery. Details of adjuvant therapy are described in supplementary Table S1 , available at Annals of Oncology online.
IGF-1R, EGRF, HER2, and c-Met expression
Representative cases with IGF-1R and EGFR protein expression of each histologic subtype are shown in Figure 1A -F. IGF-1R and EGFR expression was observed in 11 and 93 thymomas and 31 and 35 thymic carcinomas (Table 1 ). Significant differences for IGF-1R expression were detected between types A + AB and B3 (P = 0.004), type A + AB and thymic carcinoma (P < 0.001), types B1 + B2 and B3 (P = 0.004), and type B1 + B2 and thymic carcinoma (P < 0.001). Those in EGFR expression were detected between types A + AB and B1 + B2 (P = 0.001) and between type B3 and thymic carcinoma (P = 0.032). No HER2 or c-Met expression was observed in any tumor. As shown in supplementary Table S2 , available at Annals of Oncology online, the difference between IGF-1R and EGFR status was marginally significant (P = 0.088). Thus, EGFR expression was frequently observed in IGF-1R-positive thymic tumors, whereas IGF-1R expression was not always detected in EGFR-positive thymomas and thymic carcinomas.
With regards to the association between RTKs expression and clinicopathologic factors, IGF-1R and EGFR expression were significantly correlated with male sex. IGF-1R expression was significantly correlated with higher tumor stage ( Table 1) . 
IGF-1R, EGFR, HER2, and Met GCN status
Thirty-six of 133 tumors were BISH-high for IGF-1R. Among these, 28 cases exhibited high polysomy and 8 exhibited gene amplification that included >15 copies of the IGF-1R gene and small gene clusters (4-10 copies) in >10% of the tumor cells ( Figure 1G and H, Table 2 ). Statistically significant differences in IGF-1R gene amplification were detected between type A + AB or B1 + B2 and thymic carcinoma (P = 0.006 or 0.028, respectively). IGF-1R amplification was significantly correlated with higher tumor stage. Thirty-nine of 138 cases were BISH-high for EGFR. Of these, 25 cases exhibited high polysomy and 14 gene amplification (Table 2) . Statistically significant differences in EGFR copy number status were detected between types A + AB and B1 + B2, B3 thymoma, or thymic carcinoma (P = 0.032, 0.026, or < 0.001, respectively); the difference between type B1 + B2 thymoma and thymic carcinoma was also significant (P = 0.018). Those in EGFR gene amplification was detected between type A + AB and thymic carcinoma (P = 0.013). EGFR amplification was significantly correlated with female sex and lower tumor stage.
No cases were BISH-high for HER2 or c-Met. The average HER2/CEN17 and c-Met/CEN7 ratios by subtype were 1.28 and 1.01 for type A + AB, 1.28 and 1.04 for type B1 + B2, 1.09 and 1.03 for type B3, and 1.32 and 1.10 for thymic carcinoma (data not shown).
Correlations between IGF-1R or EGFR protein expression and GCN
IGF-1R protein expression was significantly correlated with gene amplification (P < 0.001, supplementary Table S3 , available at Annals of Oncology online) but not with BISH-high status (P = 0.23). In addition, EGFR protein expression and gene amplification (P = 0.29, supplementary Table S3 , available at Annals of Oncology online) or BISH-high status (P = 0.17) had no significant correlation. Discrepancies between protein expression and gene amplification for IGF-1R or EGFR were observed in 32 or 113 cases, respectively. All discrepant cases were protein expression (+)/amplification (−).
correlation between OS and clinicopathologic or histological factors
We have already reported an analysis of the clinicopathologic significance and relationship to survival of the hormone receptor expression status in this cohort [19] . shows the Kaplan-Meier OS curves according to the IGF-1R and EGFR status. The univariate survival analysis revealed that the 10-year OS rates were 85.0% and 53.5% (P = 0.0003) for patients with IGF-1R-negative and -positive tumors. The EGFR BISH-high patients had a better prognosis compared with BISH-native patients (P = 0.050). In addition, the patients with IGF-1R amplification had a poorer prognosis than those with unamplified IGF-1R (P = 0.0028). The multivariate analysis revealed that the IGF-1R amplification status (P = 0.027), thymic carcinoma (as opposed to thymoma), and higher tumor stage were significantly correlated with a poor prognosis (Table 3) .
discussion
To our knowledge, this is first report about the correlation between the IGF-1R GCN status and prognosis in thymic tumors. We found that IGF-1R expression was frequently observed in thymic carcinomas while EGFR expression was frequently detected in both thymomas and thymic carcinomas. We also found that IGF-1R protein expression was significantly correlated with true gene amplification. The IGF-1R gene amplification status was suggested to strongly predict prognosis. In contrast, no protein expression or change in GCN of c-Met or HER2 was observed in thymic epithelial tumors. As in previous reports on the IGF-1R expression rate in these tumors (87.5 to 100%) [13, 14] , 83.8% of the thymic carcinomas, most of which were Sqs, were found to express IGF-1R protein. Similar results have been detected in lung or esophageal Sqs [20, 21] . Therefore, the IGF-1R signaling pathway is likely to be an important tumorigenic factor in Sq. The expression levels of the other three RTKs were found to have no significant correlation with prognosis. However, the univariate analysis but not the multivariate analysis showed that IGF-1R-positive thymic tumors were associated with a poor prognosis. This result is similar to that of a previous report [13] , while in another report neither univariate nor multivariate analysis revealed a significant correlation [14] . The difference in the IGF-1R expression rate according to histological types is the most likely reason for this discrepancy.
The multivariate survival analysis revealed that the IGF-1R gene amplification status is an unfavorable prognostic factor compared with protein expression or the BISH status. The previous report showed the similar result on IGF-1R in non-small-cell lung cancer [20] . Therefore, patients with thymic epithelial tumors with IGF-1R gene amplification should receive adjuvant therapy after surgery. Although no statistically significant difference was detected by the multivariate analysis, the patients with no EGFR gene amplification or BISH-native tumors had worse outcomes than those with gene amplification or BISH-high status. In contrast to this result, increased EGFR GCN is known to be a poor prognostic factor in head and neck Sq [22, 23] . Therefore, the effect of the GCN status on clinical outcomes appears to vary with the organ of origin.
IGF-1R gene amplification and protein expression were significantly correlated in thymic epithelial tumors but not Missing data were excluded from the analysis. IGF-1R, insulin-like growth factor-1 receptor; EGFR, epidermal growth factor receptor; BISH, bright-field in situ hybridization; WHO, World Health Organization. EGFR. A similar result for EGFR GCN changes was demonstrated (P = 0.149) [11] . Although the cases with IGF-1R or EGFR gene amplification showed protein expression, not all cases with protein expression showed gene amplification. The protein overexpression is therefore suggested to be caused by another mechanism such as transcriptional or translational regulation. Although EGFR expression has been previously reported in about 20% to 70% of thymomas and about 50% to 100% of thymic carcinomas [11, 24] , the frequencies of positive EGFR expression in the present study were 90% and 94% in thymoma and thymic carcinoma, respectively. One possible reason for this discrepancy is the different antibody used. To our knowledge, all of the antibodies that were used in the previous studies and in the present study were different from each other. The different patient population and case number are other possible reasons. On the other hand, a high rate (12 of 57, 21.1%) of EGFR amplification was detected in type A and AB thymomas. The rate of EGFR amplification has been reported to be comparatively high in type B3 thymoma relative to other types of thymoma [24] . As for EGFR protein expression, possible reasons for this discrepancy are the differences in the population and the number. It is not clear whether our result or the previous results are more representative of the truth. However, our results provide more information about the EGFR protein expression and gene status of thymic epithelial tumors because the number of patients was significantly larger in the present study than in previous studies.
All thymomas and thymic carcinomas were found to be negative for HER2 and c-Met expression and for the BISH status. Similar result for HER2 has been demonstrated [12] . A possible reason for this lack of HER 2 and c-Met expression is that thymic epithelial tumors are of a squamous epithelial lineage. The rate of HER2 protein expression was detected at a lower rate in Sqs (5.3%) than in adenocarcinomas of the lung (9.1%) [25] . With regard to c-Met, the number of cases was also found to be fewer in Sqs (0.7% to 7.9%) than in adenocarcinomas of the lung (27.3% to 28.1%) [16, 25] . Thus, the HER2 and c-Met pathways are indicated to be less involved in the tumorigenesis of thymic tumors.
The BISH technology was performed to assess not only HER2 gene amplification but also IGF-1R, EGFR, and c-Met gene amplification. While FISH is the standard method for assessing GCN, it has some disadvantages: the fluorescent signal fades rapidly over time, and interpretation requires fluorescence microscopy. Recently, some new technologies that allow observation of gene amplification in bright fields, such as [26, 27] . Whether or not protein expression or gene amplification is a suitable predictive marker for the success of RTK therapy, the results from our series show that therapy targeted against IGF-1R or EGFR will likely be beneficial for thymic epithelial tumors, whereas therapy targeted against HER2 and c-Met will probably be less effective. Humanized monoclonal antibodies are likely to be particularly beneficial, as they target protein expression itself. A recent in vitro study demonstrated that the growth of cell lines with high IGF-1R expression is most readily inhibited by exposure to R1507, an anti-IGF-1R antibody [28] . In addition, inhibitors of heat shock protein 90 trigger the degradation of IGF-1R that contributes to establishing the antiapoptotic phenotype of thymic cancer cells [29] . Therefore, heat shock protein inhibitors are potential therapeutic agents for patients with thymic carcinoma with increased IGF-1R protein expression or IGF-1R gene amplification. Several reports have shown the efficacy of cetuximab, an EGFR-specific humanmouse chimeric monoclonal antibody, against head and neck Sq [30, 31] . Therefore, anti-IGF-1R or EGFR antibody is likely to be an effective treatment for patients with proteinoverexpressing thymic carcinomas. However, the predictive factor for this therapy is different for each target organ: in colorectal cancer, cetuximab has been demonstrated to be effective for the patients whose tumors express EGFR with the KRAS wild genotype [32] .
In summary, strong protein expression of IGF-1R and EGFR was observed in thymic carcinoma and in both thymoma and thymic carcinoma, respectively. However, IGF-1R or EGFR gene amplification was rare in thymic epithelial tumors irrespective of protein expression. No HER2 or c-Met protein expression was detected. The patients with thymic epithelial tumors with IGF-1R gene amplification were suggested to have a poor prognosis.
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